Dsuvia Tablet
Product Images NDC 61621-430

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Dsuvia (NDC 61621-430). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Acelrx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sufentanil-figure-01 (Sufentanil Figure 01)

This text provides instructions on how to administer medication from a pouch containing a single blue-colored tablet in a clear plastic SDA (sufentanil sublingual tablet) and an oxygen absorber packet. The user is instructed to tear open the notched pouch, remove the SDA from the pouch, and discard the oxygen absorber packet. Figure 1 shows a depiction of the content in the pouch.*

FDA Label Image

Sufentanil-figure-02 (Sufentanil Figure 02)

This text provides instructions for removing a white lock from a green pusher, as illustrated in Figure 2. After removing the lock, the user should discard it and take care not to accidentally eject the tablet. The text also cautions against touching the green pusher before administering the tablet to the patient. Overall, this text seems to be part of a set of instructions for administering medication.*

FDA Label Image

Sufentanil-figure-03 (Sufentanil Figure 03)

This text provides a step-by-step guide for administering medication using a sublingual drug applicator (SDA). The instructions include asking the patient to touch their tongue to the roof of their mouth, resting the SDA on the patient's lower teeth or lips, placing the SDA tip under the tongue, depressing the pusher to deliver the tablet to the sublingual space, visually confirming tablet placement, and discarding the used SDA in biohazard waste after administration. The text also includes figures to illustrate SDA placement for administration and tablet placement in the sublingual space.*

FDA Label Image

Sufentanil-figure-04 (Sufentanil Figure 04)

The text describes a graph that shows plasma concentration (measured in pg/mL) over time (up to 36 hours) after administering DSUVIA at a single dose of 30 mcg or multiple doses, represented by mean values and standard deviations.*

FDA Label Image

Sufentanil-figure-05 (Sufentanil Figure 05)

This text appears to be a graph showing the LS mean (SEM) for PID, with DSUVIA 30 mcg and placebo as the variables along the x-axis (represented at the bottom by time in hours) and the y-axis representing the values of LS mean. However, without a visual aid, it is difficult to fully assess the data shown.*

FDA Label Image

Sufentanil-figure-06 (Sufentanil Figure 06)

FDA Label Image

Sufentanil-figure-07 (Sufentanil Figure 07)

FDA Label Image

Sufentanil-figure-08 (Sufentanil Figure 08)

FDA Label Image

Sufentanil-figure-09 (Sufentanil Figure 09)

FDA Label Image

Sufentanil-figure-10.jpg (Sufentanil Figure 10)

Inactive ingredients in a medication include mannitol, dicalcium phosphate anhydrous, hydroxypropyl methylcellulose, croscarmeliose sodium, FDEC Blue #2, stearic acid, and magnesium stearate. The product is made by AcelRx Pharmaceuticals, Inc. and more information can be found on the package insert or by visiting www.dsuvia.com/video. If there are any questions, contact 1-855.925-8476. The additional information has not been approved by the FDA.*

FDA Label Image

Sufentanil-figure-11 (Sufentanil Figure 11)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.